| Name | Title | Contact Details |
|---|
MaxCyte is a US-based global company dedicated to accelerating the discovery, development, manufacturing and commercialization of next-generation, cell-based medicines.
Renovacor is a preclinical gene therapy company developing a pipeline of innovative and proprietary AAV based gene therapies for BAG3 gene mutation-associated diseases in areas of high unmet medical need. Renovacor`s therapeutic focus is initially on cardiovascular disease, with a lead program in BAG3 mutation-associated dilated cardiomyopathy.
Vivodyne accelerates the successful discovery, design, and development of human therapeutics through the convergence of novel biology, robotics, and AI. Our platform enables customers to massively de-risk drug candidates by testing them against functional, lab-grown, human organs and multi-organ systems. We conduct preclinical discovery and clinical development campaigns to generate new therapeutic strategies from these proprietary, physiologically-realistic organs at unprecedented scale, speed, and quality through automation and machine learning. We`re financially backed by some of the most selective and successful venture funds, and several “Top 10” global pharmaceutical innovators have already partnered with us to expand, strengthen, and accelerate their therapeutic pipelines.
Sage Rutty and Co is a Rochester, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Highmark Delaware is a Wilmington, DE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.